Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication 
Ebselen
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/01/2021
S-[2-[[(2R,3S,4R,5R)-3,4-Dihydroxy-5-(2-oxo-7H-pyrrolo[2,3-d]pyrimidin-3-yl)oxolan-2-yl]methoxy-[2-(2,2-dimethylpropanoylsulfanyl)ethoxy]phosphoryl]oxyethyl] 2,2-dimethylpropanethioate
Potential treatment - theoretical effect Experimental Antiviral Feb/01/2021
Calpeptin
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/01/2021
Ciluprevir
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/01/2021
PYR-41
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/01/2021
Cefpiramide
Potential treatment - theoretical effect Experimental Antiviral Jan/29/2021
N-[(2S)-1-[[(1S,2S)-1-(1,3-Benzothiazol-2-yl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
Ochromycinone
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
Pyridone 6
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
E-3G9
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
A-2F1
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
A-2H4
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
E-3B1
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
A-1H4
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
1-(3-(2,5,9-Trimethyl-7-oxo-3-phenyl-7H-furo[3,2-g]chromen-6-yl)propanoyl)piperidine-4-carboxamide
Potential treatment - theoretical effect Experimental Antiviral Jan/27/2021
5-Imidazol-1-ylmethyl-quinolin-8-ol
Potential treatment - theoretical effect Experimental Antiviral Jan/27/2021
gp96-Ig-S
Potential treatment - pre-clinical evidence Experimental Vaccine Jan/26/2021
N-[(1R)-2-(Tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/25/2021